Bodisen Biotech, Inc., the First China Based Environmentally Friendly Bio Fertilizer Company Listed on a U.S Stock Exchange to R

Name	Symbol	Market	Type
Virtus LifeSci Biotech Clinical Trials ETF	AMEX:BBC	AMEX	Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	-0.2355	-0.85%	27.4626	27.69	27.419	27.69	1,598	18:03:12

Virtus LifeSci Biotech C... (AMEX:BBC)
Historical Stock Chart

From Nov 2019 to Nov 2024

Click Here for more Virtus LifeSci Biotech C... Charts.

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Bodisen Biotech, Inc. (AMEX: BBCAMEX:website:AMEX:www.bodisen.com) will ring the opening bell at the American Stock Exchange on Thursday, September 29th, in celebration of being the first China based environmentally friendly bio fertilizer company listed on a U.S stock exchange. Bodisen became an AMEX listed company under stock symbol BBC on August 26th. Bodisen's Chairman & CEO Ms. Qiong Wang, President Bo Chen and other company management members will be present at the ceremony with AMEX officials. The event is coordinated by Wall Street firm New York Global Group and the American Stock Exchange. Ms. Qiong Wang commented: "Bodisen is very pleased with our listing on the AMEX, which we believe will reflect our status as one of the premier China- based fast growing companies listed in the US. Earlier in 2005, Forbes China ranked Bodisen one of top 100 growth companies in China. For years, Bodisen has provided environmentally friendly bio fertilizer products to a large target market, China's 900 million farmers. Bodisen is focused on its shareholders as well as exemplary corporate governance, and we believe our AMEX listing will positively impact these significant interests." Ms. Wang stated: "Bodisen's management team is delighted to be in the US and to have the opportunity to meet with our current and prospective institutional shareholders. As we continue to experience strong institutional interest in Bodisen, we look forward to another year of record earnings growth." About Bodisen Biotech, Inc. BODISEN TARGETS A LARGE AND GROWING MARKET IN CHINA Bodisen is a leading manufacturer of environmentally friendly bio fertilizer products serving the needs of China's 900 million farmers. We engage in research, manufacturing and marketing of proprietary technology based agricultural products targeting China's $17 billion per year fertilizer industry. BODISEN IS A FAST GROWING AND HIGHLY PROFITABLE COMPANY: Selected Second Quarter 2005 Results Compared to the Same Period in 2004: * Basic earnings per share of $0.18 (fully diluted: $0.17), an increase of 50% for basic earnings per share and 42% for fully diluted; * Revenue of $8,416,805, an increase of 99%; Net income of $2,692,014, an increase of 48%; * Gross profit of $3,255,664, an increase of 64% Selected First Half 2005 Results Compared to the Same Period in 2004 * Revenue of $13,118,480, an increase of 104% * Net income of $3,488,746, an increase of 55% * Gross profit increased 72% compared to the six month period ended June 30, 2004 * Basic earnings per share of $0.23 (fully diluted: $0.22), an increase of 53% for basic earnings per share and 47% for fully diluted BODISEN FACES FAVORABLE MARKET ENVIRONMENT IN CHINA We are a unique company in a favorable market environment. China exports many things to the world marketplace; however is one of the largest importers of grains and foods in the world. Hundreds of millions of Chinese depend on imported grains to support higher demand for meat and poultry which are fed with imported grains. The Chinese government has mandated that farmers increase crop yields to decrease the nation's dependence on foreign imports. Moreover, there is growing emphasis on the need for "green" fertilizers that restore the soil, rather than deplete it. BODISEN HAS A FULL LINE OF PRODUCTS THAT EFFECTIVELY ADDRESS COMPLETE PLANTING NEEDS OF CHINESE FARMERS With over 60 products and approximately 600 national distribution centers and growing, Bodisen has experienced rapid growth in recent years. Bodisen's products are developed by company scientists in collaboration with University laboratories. Our products address grains, vegetables, fruit crops and have been proven to increase yields by 10% to 35% while 100% environmentally friendly. Our products substantially improve the lifestyles of the 900 million Chinese farmers whose livelihood are solely dependent upon their crop yields. EARNINGS GUIDANCE FOR YEAR 2005 Bodisen affirmed fiscal 2005 (December yearend) guidance for earnings of approximately $8 million (including 1Q05 one time financing related charge), or approximately 50 cents per share, on revenue of approximately $28 million. Guidance does not include positive impact from increased sales channels and further expansion of manufacturing capacities, as a result of the Company's planned dual listing before yearend on the AIM market of the London Stock Exchange raising up to 10 million British Pound (US$18 million) through placement of new shares (Broker: UK investment bank Charles Stanley; Reporting accountant: Deloitte & Touche). Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. DATASOURCE: Bodisen Biotech, Inc. CONTACT: Bodisen Biotech, Inc., Investor Relations, +1-212-566-3503, Web site: http://www.bodisen.com/

	Real-time Prices	Level 2
London Stock Exchange
Chi-X Europe
BATS Europe
Aquis Exchange
FTSE Indices
Euronext
New York Stock Exchange
NASDAQ
American Stock Exchange
Dow Jones Indices
Forex
Precious Metal

London Stock Exchange
Advanced charts
Premium community
Data download

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

BBC Virtus LifeSci Biotech Clinical Trials ETF